WO2015081701A1 - 广金钱草总黄酮胶囊及其制备方法和应用 - Google Patents
广金钱草总黄酮胶囊及其制备方法和应用 Download PDFInfo
- Publication number
- WO2015081701A1 WO2015081701A1 PCT/CN2014/082224 CN2014082224W WO2015081701A1 WO 2015081701 A1 WO2015081701 A1 WO 2015081701A1 CN 2014082224 W CN2014082224 W CN 2014082224W WO 2015081701 A1 WO2015081701 A1 WO 2015081701A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- desmodium
- total flavonoids
- total
- Prior art date
Links
- 150000002215 flavonoids Chemical class 0.000 title claims abstract description 408
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 407
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 407
- 239000002775 capsule Substances 0.000 title claims abstract description 195
- 238000000034 method Methods 0.000 title claims abstract description 110
- 244000227573 Desmodium styracifolium Species 0.000 title abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 273
- 239000000284 extract Substances 0.000 claims abstract description 149
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 241000522190 Desmodium Species 0.000 claims description 134
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 107
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 100
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 98
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 98
- 239000008101 lactose Substances 0.000 claims description 98
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 98
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 98
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 98
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 81
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 81
- 229940069328 povidone Drugs 0.000 claims description 81
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 77
- 239000003814 drug Substances 0.000 claims description 74
- 229960001375 lactose Drugs 0.000 claims description 64
- 229940079593 drug Drugs 0.000 claims description 61
- 238000002360 preparation method Methods 0.000 claims description 57
- 239000000463 material Substances 0.000 claims description 49
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 45
- 239000000741 silica gel Substances 0.000 claims description 44
- 238000005469 granulation Methods 0.000 claims description 43
- 230000003179 granulation Effects 0.000 claims description 43
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 41
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 41
- 239000011347 resin Substances 0.000 claims description 39
- 229920005989 resin Polymers 0.000 claims description 39
- 235000019359 magnesium stearate Nutrition 0.000 claims description 38
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 37
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 34
- 238000001179 sorption measurement Methods 0.000 claims description 31
- 239000007921 spray Substances 0.000 claims description 29
- 229910002055 micronized silica Inorganic materials 0.000 claims description 27
- 239000002994 raw material Substances 0.000 claims description 27
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 23
- 238000010992 reflux Methods 0.000 claims description 23
- 239000011230 binding agent Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 20
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000945 filler Substances 0.000 claims description 19
- 239000000314 lubricant Substances 0.000 claims description 18
- 239000000853 adhesive Substances 0.000 claims description 17
- 230000001070 adhesive effect Effects 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 16
- 229960000913 crospovidone Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 15
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 15
- 239000007884 disintegrant Substances 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229960003943 hypromellose Drugs 0.000 claims description 13
- 239000012535 impurity Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 12
- 208000009911 Urinary Calculi Diseases 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000000889 atomisation Methods 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229940032147 starch Drugs 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 235000020985 whole grains Nutrition 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229940112824 paste Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 241000521456 Desmodium cuspidatum Species 0.000 claims 8
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
- 241000612166 Lysimachia Species 0.000 description 99
- 241001465754 Metazoa Species 0.000 description 40
- 238000004090 dissolution Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 33
- 230000008569 process Effects 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- 239000004575 stone Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 22
- 244000025254 Cannabis sativa Species 0.000 description 21
- 240000003421 Dianthus chinensis Species 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 241000700159 Rattus Species 0.000 description 17
- 150000004676 glycans Chemical class 0.000 description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 17
- 229920001282 polysaccharide Polymers 0.000 description 17
- 239000005017 polysaccharide Substances 0.000 description 17
- 235000008216 herbs Nutrition 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 241000208422 Rhododendron Species 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 241000192700 Cyanobacteria Species 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000009825 accumulation Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- 208000000913 Kidney Calculi Diseases 0.000 description 6
- 206010029148 Nephrolithiasis Diseases 0.000 description 6
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 6
- 238000011047 acute toxicity test Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000007599 discharging Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 229910021487 silica fume Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 4
- 244000020518 Carthamus tinctorius Species 0.000 description 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 231100001252 long-term toxicity Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 230000008925 spontaneous activity Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010020524 Hydronephrosis Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010007027 Calculus urinary Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 235000008597 Diospyros kaki Nutrition 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 231100000570 acute poisoning Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000006068 polycondensation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000234281 Tamarix gallica Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Definitions
- the invention belongs to the field of traditional Chinese medicine, and particularly relates to a total flavonoid capsule of the medicinal herb, and a preparation method and application thereof. More specifically, the present invention relates to a total flavonoid capsule of Herba Scutellariae and a preparation method thereof, and an application of a total flavonoid capsule of Herba Lysimachia in the preparation of a medicament for treating urinary calculi. Background technique
- the broad-leaved part of the medicinal plant is a traditional Chinese medicine contained in the Chinese Pharmacopoeia 2010 edition, with a dampness and yellowing, diuretic The effect.
- the prescription preparation of Shilintong tablets is mainly composed of broad-leaf grass, which is used for moist heat of the bladder, stone dripping pain, urinary calculi, and urinary tract infection is hepatobiliary bladder damp heat.
- the preparation of the raw material of Shilintong Tablet is a crude extract of Dianthus chinensis obtained by the traditional water extraction and alcohol precipitation extraction process.
- the drug still has a clear basis for the pharmacodynamic substance and the clinical dose is too large. (6 times a day, 3 tablets each time, sugar-coated tablets or film-coated tablets, each containing 0.12 g of dry extract), and the quality control standards are not perfect.
- Western medicine is commonly used in the treatment of urinary calculi, such as potassium citrate, thiazide diuretics, magnesium, acetylcysteine, etc., and its efficacy is not satisfactory, and the toxicity and side effects are obvious.
- Chinese patent medicines such as Shishitong, Paishi Granules, and Shilintong tablets are commonly used drugs with exact curative effects.
- an object of the present invention is to provide an effective material basis, controllable quality standards, good drug dissolution, good quality stability, remarkable pharmacological effects, low dosage, safe and convenient administration, and fully suitable for industrialized production.
- the present invention is based on the following findings of the inventors:
- the chemical constituents of the medicinal herbs are flavonoids, alkaloids, phenols, tannins, polysaccharides, etc., wherein the flavonoid component is its main medicinal ingredient.
- Pharmacological studies have shown that the effective part of the polysaccharide (the effective substance), the total flavonoids of the Chinese medicinal herb have obvious pharmacological effects such as dissolving stone, discharging stones, and reducing the formation of new stones.
- Oral solid preparations have many disadvantages such as slow dissolution, unstable product quality, low bioavailability, and low clinical efficacy. Because the absorption of the drug is premised on dissolution, the bioavailability in the body has a certain correlation with the dissolution characteristics in vitro. Therefore, the dissolution of the drug directly affects the absorption of the drug, and the dissolution of the drug in the preparation is whether the drug can be Take control of its efficacy. Further, to increase the absorption rate of the oral preparation in the human body, the most important thing is to increase the dissolution and release of the drug, thereby increasing the maximum blood concentration of the oral active ingredient after 3 hours.
- the present invention provides a total flavonoid of Lysimachia chinensis.
- the total flavonoids of the cynomolgus sinensis is an alcohol extract of the polysaccharide, and the total flavonoid content of the cynomolgus sinensis (in dry matter, %) is 50. %-80%, wherein the content of the safariin (% by dry product) is 3.0% to 12.0%.
- the total flavonoids of Rhododendron chinense are prepared by the following steps: adding alcohol extract to alcohol extract to obtain extract of Dianthus chinensis, and purifying the extract of Lysimachia chinensis to obtain The broad-leaf grass extract.
- the alcohol extraction of the polysaccharides further comprises: heating and refluxing the medicinal herbs with 50% to 95% ethanol of 8 to 14 times the weight of the medicinal materials, and extracting 1-3 times. Each time for 1 to 3 hours, the alcohol extract is combined to obtain the extract of the broad-leaved grass.
- purifying the extract of the broad-leaf grass extract further comprises: concentrating the extract of the broad-leaf grass extract to remove ethanol; and performing the macroporous adsorption resin column on the extract of the broad-leaf grass extract Treatment to obtain purified total flavonoids of Herba Lysimachia.
- the method of preparing the total flavonoids of the broadbread of the present invention may comprise the following steps:
- the alcohol extract is concentrated to a certain volume, so that the volume of the liquid is 2 to 8 times the amount of the medicine, and after standing and filtering, the filtrate is obtained; c the filtrate passes through the AB-8 at a flow rate of 1 to 3 times per minute of the bed volume.
- the pore adsorption resin column after the adsorption is completed, first elute with 8 ⁇ 12 times of resin amount of water, and then use 6 ⁇ 10 times the bed volume of 40% ⁇ 95% ethanol to
- Elution is carried out at a flow rate of 2 to 4 times the volume of the column bed to obtain an eluent
- the eluent is recovered from ethanol and concentrated to a concentrated solution having a relative density of 1.10 ⁇ 1.30.
- the concentrated solution is dried and pulverized to obtain a total flavonoid extract of Herba fuliginea, and the total flavonoid content in the extract can reach 50%-80%. , wherein the content of sedumin is from 3.0% to 12.0%. Collect the dried extract, seal, weigh, and store in a dry place.
- the ethanol concentration referred to in the present invention means the volume fraction (V/V) of ethanol contained in a 100 mL volume of aqueous ethanol solution.
- the method for preparing a total flavonoid extract of Dioscorea opposita L. according to the present invention may comprise the following steps:
- the eluate is recovered from ethanol, concentrated to a concentrated liquid having a relative density of 1.22, and the concentrated solution is dried under reduced pressure at 75 ° C, and pulverized to obtain a total flavonoid extract product of Herba Lysimachia.
- the preparation process and technical parameters of the total flavonoid extract of Herba Lysimachia chinensis are carefully investigated and studied, and the optimal conditions are selected, and the pilot process is verified. , Successfully transitioned to industrial production.
- the invention improves the content of active ingredients and effective substances in the medicinal herbs of the medicinal herbs, and the total flavonoid content of the cynomolgus sinensis (in terms of dry products) is 50%-80%, wherein the buddha is The glucoside content (% by dry product) is from 3.0% to 12.0%.
- the present invention provides a total flavonoid capsule of Herba Lysimachia.
- the total flavonoid capsule of the broad-leaved grass comprises: a total flavonoid of Lysimachia chinensis as an active ingredient, wherein the total flavonoid of the cynomolgus sinensis is provided in the form of an extract of oleracea alcohol.
- the extract of the polysaccharide of the oleic acid is obtained by the following steps: heating and refluxing the medicinal material of the medicinal herb with ethanol to obtain a extract of the cynomolgus extract, wherein the concentration of the ethanol is 50 ⁇ 95%, the weight of the ethanol is 8 to 14 times that of the medicinal herbs; the concentrated extract of the cyanobacteria is concentrated to remove ethanol; and the concentrated extract of the cypress grass is subjected to concentration treatment.
- the macroporous adsorption resin column is treated to obtain the extract of the polysaccharide of the polysaccharide.
- the extract of the Lycium chinensis is heated and refluxed by using 50% to 95% ethanol of the weight of the medicinal material of 8 to 14 times the weight of the herbal medicine, and extracting 1-3 times, each time 1 ⁇ 3 hours, and obtained by combining alcohol extracts.
- the inventors have found that the total flavonoid capsule of the broad-leaf medicinal herb prepared by the present invention has high drug dissolution rate, remarkable clinical curative effect, small adverse reaction, and urinary calculi disease, especially pyelone stone and ureteral stone disease. Very good therapeutic effect, its therapeutic effect is better than the existing drug Shilintong tablets.
- the active ingredient and content of the total flavonoid capsule of the broad-growing grass of the invention are clear, the quality is stable and controllable; the preparation has a large drug loading amount, the dosage is small, and the absorption in the body is better; the administration is convenient, the use is simple, the price is cheap, and the economy is practical. .
- the total flavonoid capsule of the present invention may comprise: a total flavonoid raw material of Lysimachia chinensis, and a pharmaceutically acceptable pharmaceutically acceptable excipient.
- the total flavonoids of D. chinensis are an alcohol extract of D. chinensis, and are prepared according to the method for preparing total flavonoids of D.
- the pharmaceutically acceptable pharmaceutical excipient may include a filler, a binder.
- the filler is selected from the group consisting of jade At least one of rice starch, dextrin, lactose, pregelatinized starch, sucrose, microcrystalline cellulose, mannitol, sorbitol, xylitol, calcium hydrogen phosphate, calcium carbonate, preferably filler is xylitol, micro At least one of crystalline cellulose and lactose.
- the binder is selected from the group consisting of starch paste, hypromellose, microcrystalline cellulose, povidone K 3Q , povidone K 25 , polyethylene glycol 6000, methyl At least one of cellulose and ethanol, preferably a binder, is at least one of polyethylene glycol 6000, povidone K 3Q , hypromellose, and microcrystalline cellulose.
- the pharmaceutically acceptable pharmaceutical excipient may further include a wetting agent, a disintegrating agent, and a lubricant.
- the wetting agent is a solvent which is at least one selected from the group consisting of water and ethanol.
- the disintegrant is selected from the group consisting of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crospovidone, dry starch, croscarmellose sodium, and carboxymethyl
- the lubricant is selected from the group consisting of magnesium stearate, talc, micronized silica gel, sodium decyl sulfate, sodium decyl sulfate, sodium benzoate, and stearyl fumarate.
- At least one of sodium, preferably a lubricant, is at least one of magnesium stearate, silica gel, and sodium stearyl fumarate.
- the total flavonoid capsule of the present invention may comprise: 33-400 parts by weight of total flavonoids of Lysimachia chinensis, 30-120 parts by weight of filler, 0.1-10 weight of adhesive, according to parts by weight. Parts, disintegrating agent 1-80 parts by weight, lubricant 1-10 parts by weight, wetting agent 80-210 parts by weight.
- the total flavonoid capsule of the present invention may comprise: 33 parts by weight of total flavonoids of Lysimachia chinensis, 66 parts by weight of microcrystalline cellulose, 66 parts by weight of lactose, povidone according to parts by weight. 1 part by weight of K 3Q , 10 parts by weight of croscarmellose sodium, 1 part by weight of sodium stearyl fumarate, and 120 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 33 parts by weight of total flavonoids of Lysimachia chinensis, 33 parts by weight of microcrystalline cellulose, 33 parts by weight of lactose, and cross-linked polycondensation. 60 parts by weight of ketene, 5 parts by weight of polyethylene glycol 6000, 5 parts by weight of sodium stearyl fumarate, and 120 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 50 parts by weight of total flavonoids of Radix Paeoniae Alba, 50 parts by weight of microcrystalline cellulose, 50 parts by weight of lactose, and polyethylene. 2 parts by weight of alcohol 6000, 2 parts by weight of magnesium stearate, 120 parts by weight of ethanol, and 40 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 66.5 parts by weight of total flavonoids of Radix Paeoniae Alba, 40 parts by weight of microcrystalline cellulose, and croscarmellose sodium according to parts by weight. 40 parts by weight, 30 parts by weight of crospovidone, 10 parts by weight of polyethylene glycol 6000, 5 parts by weight of magnesium stearate, and 200 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 66.5 parts by weight of total flavonoids of Radix Paeoniae Alba, 50 parts by weight of microcrystalline cellulose, 50 parts by weight of lactose, carboxymethyl group. 30 parts by weight of cellulose calcium, povidone K 3 . 2 parts by weight, 5 parts by weight of magnesium stearate, and 180 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 80 parts by weight of total flavonoids of Lysimachia chinensis, 35 parts by weight of microcrystalline cellulose, 30 parts by weight of lactose, povidone according to parts by weight. K 3Q 0.1 weight Parts, 5 parts by weight of magnesium stearate, and 80 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 100 parts by weight of total flavonoids of Lysimachia chinensis, 60 parts by weight of lactose, and 35 parts by weight of croscarmellose sodium. 0.1 parts by weight of hypromellose, 2 parts by weight of silica gel of micronized powder, 100 parts by weight of ethanol, and 10 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 100 parts by weight of total flavonoids of Radix Paeoniae Alba, 40 parts by weight of microcrystalline cellulose, and croscarmellose sodium according to parts by weight. 20 parts by weight, 40 parts by weight of crospovidone, 10 parts by weight of polyethylene glycol 6000, 10 parts by weight of magnesium stearate, and 210 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 120 parts by weight of total flavonoids of D. chinensis, 40 parts by weight of microcrystalline cellulose, 40 parts by weight of lactose, and polyethylene. 6000 parts by weight of alcohol, 2 parts by weight of magnesium stearate, and 120 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 120 parts by weight of total flavonoids of Lysimachia chinensis, 120 parts by weight of lactose, 1 part by weight of hypromellose, and stearic acid. 1 part by weight of magnesium sulfate, 100 parts by weight of ethanol, and 20 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 120 parts by weight of total flavonoids of D. chinensis, 40 parts by weight of microcrystalline cellulose, 40 parts by weight of lactose, and polyethylene.
- Alcohol 6000 1 part by weight, povidone K 3 . l parts by weight, 2 parts by weight of micronized silica gel, 96 parts by weight of ethanol, and 24 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 133 parts by weight of total flavonoids of Radix Paeoniae Alba, 30 parts by weight of microcrystalline cellulose, 37 parts by weight of lactose, povidone according to parts by weight. 1 part by weight of K 3Q and 120 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 133 parts by weight of total flavonoids of Radix Paeoniae Alba, 30 parts by weight of microcrystalline cellulose, 37 parts by weight of lactose, povidone according to parts by weight. 1 part by weight of K 3Q , 20 parts by weight of croscarmellose sodium, 1 part by weight of fine silica gel, and 120 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 133 parts by weight of total flavonoids of Radix Paeoniae Alba, 33 parts by weight of microcrystalline cellulose, 33 parts by weight of lactose, povidone according to parts by weight. 1 part by weight of K 3Q , 15 parts by weight of croscarmellose sodium, 1 part by weight of fine silica gel, and 120 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 150 parts by weight of total flavonoids of Radix Paeoniae Alba, 30 parts by weight of microcrystalline cellulose, 30 parts by weight of lactose, and cross-linked polycondensation. 80 parts by weight of ketene, 5 parts by weight of polyethylene glycol 6000, 5 parts by weight of sodium stearyl fumarate, 130 parts by weight of ethanol, and 45 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 150 parts by weight of total flavonoids of Radix Paeoniae Alba, 30 parts by weight of microcrystalline cellulose, 20 parts by weight of lactose, povidone according to parts by weight. K 3Q 1.2 parts by weight, 2 parts by weight of micronized silica gel, and 80 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 200 parts by weight of total flavonoids of Radix Paeoniae Alba, 30 parts by weight of microcrystalline cellulose, 30 parts by weight of lactose, povidone according to parts by weight. K 3Q 2 parts by weight, 120 parts by weight of silica powder 2 parts by weight of water.
- the total flavonoid capsule of the present invention may comprise: 400 parts by weight of total flavonoids of Radix Paeoniae Alba, 50 parts by weight of microcrystalline cellulose, 50 parts by weight of lactose, povidone according to parts by weight. K 3Q 2 parts by weight, 4 parts by weight of micronized silica gel, and 200 parts by weight of water.
- the present invention provides a method of preparing a total flavonoid capsule of Herba Lysimachia.
- the method comprises: providing total flavonoids of Lysimachia chinensis, the total flavonoids of the genus Diospyros chinensis, an alcohol extract of Dianthus chinensis, and the use of pharmaceutically acceptable pharmaceutically acceptable excipients
- Rhododendron chinense The total flavonoid extract of Rhododendron chinense is insoluble in water, but since the powder of the extract of Dianthus chinensis is sticky after water (increased viscosity), it is found in the manual granulation process of the small test that the granulation effect is very poor, almost Can not be granulated. After switching to machine granulation, although the granulation effect is improved, the dissolution rate is between 73 and 78%, and the difference between the batch and the batch is large. Through the test, the quality of the product will not be in the long-term staking process. Qualified risk. Dissolution was also not improved by screening and optimizing the prescription.
- the inventors have obtained the desired beneficial effects.
- the inventors unexpectedly discovered that by changing the granulation process, the original ordinary wet granulation process was changed to the fluidized bed granulation process, and it was found that the fluidized bed granulation effect was significantly improved, compared with the original process, the new process.
- the process significantly improves the dissolution of the total flavonoid capsules of the polysaccharide, and the dissolution rate can be stabilized between 88-92%, and the difference in dissolution between the batch and the batch is small.
- the method effectively ensures the quality of the product, improves the stability of the formulation of the active ingredient, improves the dissolution of the drug, and has simple process and strong operability, and is completely suitable for industrial large-scale production.
- the preparation of the total flavonoid extract of Rhododendron chinense further comprises the steps of: extracting alcohol extracts to obtain the extract of Dianthus chinensis, and purifying the extract of Dianthus chinensis, In order to obtain the extract of the broadgrass.
- the alcohol extraction of the polysaccharides further comprises: heating and refluxing the medicinal herbs with 50% to 95% ethanol of 8 to 14 times the weight of the medicinal materials, and extracting 1-3 times. Each time for 1 to 3 hours, the alcohol extract is combined to obtain the extract of the broad-leaved grass.
- purifying the extract of the broad-leaf grass extract further comprises: concentrating the extract of the broad-leaf grass extract to remove ethanol; and performing the macroporous adsorption resin column on the extract of the broad-leaf grass extract Treatment to obtain purified total flavonoids of Herba Lysimachia.
- the pharmaceutically acceptable pharmaceutically acceptable excipient may include a filler, a binder.
- the pharmaceutically acceptable pharmaceutically acceptable excipient may further comprise a wetting agent or a disintegrating agent. , lubricants.
- the preparation of the total flavonoids of the cyanobacteria can further comprise: using a pharmaceutically acceptable drug Using excipients, The total flavonoids of Rhododendron chinense and medicinal excipients are mixed to prepare a capsule.
- the method for preparing the total flavonoids of the cyanobacteria can further comprise: mixing the total flavonoids of the cyanobacteria with a pharmaceutically acceptable excipient, using a fluidized bed granulation process, preheating, spraying , drying, cooling, mixing, granulating, and then capsule filling, in order to obtain the total flavonoid capsules of the broad money grass.
- the use of the fluidized bed granulation process to mix the extract raw material of the total flavonoids of the broadleaf sinensis with the medicinal excipient further comprises: respectively, the prescribed amount of the total flavonoid extract of the broadleaf And a filler, a binder, a disintegrant, a lubricant, a sieve of 40-120 mesh; a binder is added to the solvent and stirred, and configured to be used as a solution; according to the prescription, the total flavonoids of the herb, and the filler
- using the fluidized bed granulation process to form the total flavonoids of the broad-leaved turfgrass into the total flavonoids of the cyanobacteria can further comprise: And a pharmaceutically acceptable pharmaceutically acceptable excipient, passing through a 60-100 mesh sieve; dissolving the binder in a solvent and stirring, and formulating the solution for use; according to the prescription, the total flavonoids of the cyanobacteria and the filler are used as materials
- preheat for 5 to 60 minutes, preheat to 35 ° C -55 ° C; adjust the parameters, and spray the binder solution into the fluidized bed using a spray gun to granulate, maintaining the atomization pressure 0.7-1.0 bar (1 bar 0.1 MPa), the spray speed is 15-25 rpm, and the temperature of the material is kept at 40 °C-55 °C by adjusting the inlet air temperature of 50 °C-65 °C.
- the adhesive is sprayed.
- the parameters to dry. Adjust the inlet air temperature by 60 ° C - 7 (TC, raise the temperature of the material to 40 ° C - 55 ° C, and dry for 5 to 60 minutes. Cooling and discharging the dried granules, mixing with the disintegrant in the mixer, By 40-80 mesh; whole, adding a lubricant uniformly mixed for filling a capsule, to obtain capsules Desmodium total flavonoids.
- the filler be at least one of xylitol, microcrystalline cellulose, and lactose.
- the binder is at least one of polyethylene glycol 6000, povidone K 3Q , hypromellose.
- the wetting agent is water.
- the disintegrant is at least croscarmellose sodium, crospovidone, carboxymethylcellulose calcium.
- the disintegrant is at least croscarmellose sodium, crospovidone, carboxymethylcellulose calcium.
- the lubricant is at least one of magnesium stearate, silica gel, and sodium stearyl fumarate.
- the total flavonoid capsule of the broadbread of the present invention is in parts by weight, and the ratio of each raw material is: 33-400 parts by weight of total flavonoids of Lysimachia chinensis, 30-120 parts by weight of filler, 0.1 of binder From 10 parts by weight, from 1 to 80 parts by weight of the disintegrant, from 1 to 10 parts by weight of the lubricant, and from 80 to 210 parts by weight of the wetting agent.
- the ratio of each raw material is 33 parts by weight of total flavonoids, 66 parts by weight of microcrystalline cellulose, 66 parts by weight of lactose, and 1 part by weight of povidone K 3Q, in parts by weight. 10 parts by weight of croscarmellose sodium, 1 part by weight of sodium stearyl fumarate, and 120 parts by weight of water.
- the ratio of each raw material is 33 parts by weight of total flavonoids, 33 parts by weight of microcrystalline cellulose, 33 parts by weight of lactose, 60 parts by weight of crospovidone, according to parts by weight. 5 parts by weight of polyethylene glycol 6000, 5 parts by weight of sodium stearyl fumarate, and 120 parts by weight of water.
- the ratio of each raw material is 50 parts by weight of total flavonoids, 50 parts by weight of microcrystalline cellulose, 50 parts by weight of lactose, and 2 parts by weight of polyethylene glycol. 2 parts by weight of magnesium stearate, 120 parts by weight of ethanol, and 40 parts by weight of water.
- the ratio of each raw material is 66.5 parts by weight of total flavonoids, 40 parts by weight of microcrystalline cellulose, 40 parts by weight of croscarmellose sodium, cross-linking according to parts by weight. 30 parts by weight of povidone, 10 parts by weight of polyethylene glycol 6000, 5 parts by weight of magnesium stearate, and 200 parts by weight of water.
- the ratio of each raw material is 66.5 parts by weight of total flavonoids, 50 parts by weight of microcrystalline cellulose, 50 parts by weight of lactose, and 30 parts by weight of carboxymethylcellulose calcium. 2, parts by weight of povidone K 30 , 5 parts by weight of magnesium stearate, and 180 parts by weight of water.
- the ratio of each raw material is 80 parts by weight of total flavonoids, 35 parts by weight of microcrystalline cellulose, 30 parts by weight of lactose, 0.1 parts by weight of povidone K 3Q, in parts by weight, 5 parts by weight of magnesium stearate and 80 parts by weight of water.
- the ratio of each raw material is 100 parts by weight of total flavonoids, 60 parts by weight of lactose, 35 parts by weight of croscarmellose sodium, hypromellose according to parts by weight. 0.1 parts by weight, 2 parts by weight of micronized silica gel, 100 parts by weight of ethanol, and 10 parts by weight of water.
- the ratio of each raw material is 100 parts by weight of total flavonoids, 40 parts by weight of microcrystalline cellulose, 20 parts by weight of croscarmellose sodium, cross-linking according to parts by weight. 40 parts by weight of povidone, 10 parts by weight of polyethylene glycol 6000, 10 parts by weight of magnesium stearate, and 210 parts by weight of water.
- the ratio of each raw material is 120 parts by weight of total flavonoids, 40 parts by weight of microcrystalline cellulose, 40 parts by weight of lactose, and 2 parts by weight of polyethylene glycol. 2 parts by weight of magnesium stearate and 120 parts by weight of water.
- the ratio of each raw material is 120 parts by weight of total flavonoids, 120 parts by weight of lactose, 1 part by weight of hypromellose, and 1 part by weight of magnesium stearate. 100 parts by weight of ethanol and 20 parts by weight of water.
- the ratio of each raw material is 120 parts by weight of total flavonoids, 40 parts by weight of microcrystalline cellulose, 40 parts by weight of lactose, and 1 part by weight of polyethylene glycol, according to parts by weight.
- Povidone K 30 l parts by weight, 2 parts by weight of micronized silica gel, 96 parts by weight of ethanol, and 24 parts by weight of water.
- the ratio of each raw material is in parts by weight: total flavonoids 133 Parts by weight, 30 parts by weight of microcrystalline cellulose, 37 parts by weight of lactose, 128 parts by weight of povidone K 3Q , and 120 parts by weight of water.
- the ratio of each raw material is 133 parts by weight of total flavonoids, 30 parts by weight of microcrystalline cellulose, 37 parts by weight of lactose, and 128 parts by weight of povidone K 3Q, in parts by weight. 20 parts by weight of croscarmellose sodium, 1 part by weight of micronized silica gel, and 120 parts by weight of water.
- the ratio of each raw material is 133 parts by weight of total flavonoids, 33 parts by weight of microcrystalline cellulose, 33 parts by weight of lactose, and 128 parts by weight of povidone K 3Q, in parts by weight. 15 parts by weight of croscarmellose sodium, 1 part by weight of micronized silica gel, and 120 parts by weight of water.
- the ratio of each raw material is 150 parts by weight of total flavonoids, 30 parts by weight of microcrystalline cellulose, 30 parts by weight of lactose, 80 parts by weight of crospovidone, according to parts by weight. 5 parts by weight of polyethylene glycol 6000, 5 parts by weight of sodium stearyl fumarate, 130 parts by weight of ethanol, and 45 parts by weight of water.
- the ratio of each raw material is 150 parts by weight of total flavonoids, 30 parts by weight of microcrystalline cellulose, 20 parts by weight of lactose, 1.2 parts by weight of povidone K 3Q, in parts by weight, 2 parts by weight of micronized silica gel and 80 parts by weight of water.
- the ratio of each raw material is 200 parts by weight of total flavonoids, 30 parts by weight of microcrystalline cellulose, 30 parts by weight of lactose, and 128 parts by weight of povidone, according to parts by weight. 2 parts by weight of micronized silica gel and 120 parts by weight of water.
- the ratio of each raw material is 400 parts by weight of total flavonoids, 50 parts by weight of microcrystalline cellulose, 50 parts by weight of lactose, and 128 parts by weight of povidone, according to parts by weight. 4 parts by weight of micronized silica gel and 200 parts by weight of water.
- the method for preparing a total flavonoid capsule of the herb of the present invention may comprise the following steps:
- the impurity is eluted with 8 ⁇ 12 times of resin amount of water, and then 6 ⁇ 10 times of the bed volume of 40% ⁇ 95% ethanol is used. 2 ⁇ 4 times the volume of the bed volume is eluted to obtain an eluent; the eluate is recovered into ethanol, concentrated to a concentration of 1.10 ⁇ 1.30, and the concentrate is dried and pulverized to obtain total flavonoids of Herba Lysimachia. Extract
- the method for preparing a total flavonoid capsule of the herb of the present invention may comprise the following steps:
- the impurity was eluted with 10 times of resin amount, and then 8 times of bed volume of 60% ethanol was used. Elution was carried out at a flow rate of 2 times the bed volume of the column to obtain an eluate; the eluate was recovered into ethanol, concentrated to a concentrate having a relative density of 1.22, and the concentrate was dried under reduced pressure at 75 ° C, and pulverized to obtain a broad grass.
- An extract of total flavonoids
- the method for preparing a total flavonoid capsule of the herb of the present invention may comprise the following steps:
- the impurity was eluted with 10 times of resin amount, and then 8 times of bed volume of 60% ethanol was used. Elution was carried out at a flow rate of 2 times the bed volume of the column to obtain an eluate; the eluate was recovered into ethanol, concentrated to a concentrate having a relative density of 1.22, and the concentrate was dried under reduced pressure at 75 ° C, and pulverized to obtain a broad grass.
- An extract of total flavonoids
- the dried granules are cooled and discharged, passed through a 60-mesh sieve, and the whole capsule is filled into capsules to obtain the total flavonoid capsule of the medicinal herb.
- the inventors experimented with three batches of total flavonoids of Herba Lysimachia var. chinensis by the method according to the embodiment of the present invention, and conducted preliminary investigation on the stability thereof.
- the influencing factors test were carried out respectively.
- the results showed that the total flavonoid capsule of D. chinensis under light conditions Stable, high temperature 60 ° C and relative humidity 75% for 10 days, 40 ° C accelerated test for 6 months, long-term test conditions for 6 months, physical and chemical indicators did not change significantly.
- the present invention provides a total flavonoid capsule of Herba Lysimachia.
- the total flavonoid capsule of the cynomolgus sinensis is prepared by the method for preparing the total flavonoid capsule of the cyanobacteria described above.
- the present invention provides a medical use of a total flavonoid capsule of Herba Lysimachia.
- the total flavonoid capsule of the medicinal herb obtained by the present invention can be used for the preparation of a clinical therapeutic drug for treating moist heat removal and diuretic drainage (damp heat accumulation).
- Total flavonoids of Rhododendron chinense can significantly inhibit the amount of calcium oxalate crystal aggregates in the kidney, reduce the formation rate of kidney stones and serum creatinine and uric acid content, and improve rat kidney Function; It has the function of dissolving stone and reducing the formation of new stones; It has diuretic effect; and the total flavonoids of Radix Paeoniae Alba can alleviate the swelling degree and swelling rate caused by injection of fresh egg white in rats, suggesting that the total flavonoid capsule of Polysaccharide sinensis has certain anti-inflammatory effect. It has a significant inhibitory effect on granulation tissue proliferation.
- the acute toxicity test of the total flavonoid capsule of the medicinal herb of the Chinese medicinal herb showed that: the total flavonoids of the cynomolgus sinensis is a substantially non-toxic test drug.
- the acute toxicity test results of the total flavonoids of Rhizoma Polysaccharide in rats showed that: Total flavonoids of Radix Paeoniae Alba is a test drug without serious acute poisoning.
- the long-term toxicity test results of the animals also proved that the total flavonoids of D. chinensis were safe.
- the invention has the following advantages:
- the invention selects the effective part of the total flavonoids of Lysimachia chinensis from the broad-leaved genus, and utilizes the techniques of macroporous resin to study the production process of extracting and separating the insoluble soluble total flavonoids of the cyanobacteria, and the traditional Chinese medicine preparation for fluidized bed granulation.
- the process in turn, developed a new Chinese medicine, a new traditional Chinese medicine for the treatment of urolithiasis, and provided a good dissolution and quality stability.
- ethanol is used as an extraction solvent to extract the medicinal materials of the medicinal herbs, and the extract is purified by macroporous adsorption resin to obtain the total flavonoids of the genus Lysimachia chinensis.
- the effective material basis of the extract is clear, the quality standard is controllable, the clinical dose of the drug is reduced, and the clinical adverse reaction is reduced.
- the invention can recover the ethanol to a certain volume (5 times the amount of the medicine) and directly purify the macroporous resin without concentrating and drying to the extract, saving Production time; Secondly, after the macroporous resin is used, the higher concentration of the active ingredient can be obtained by eluting with the same concentration of ethanol. Compared with the gradient elution with different concentrations of ethanol, the process flow is simple and the operability is strong; After the eluent recovers the ethanol, it is directly dried under reduced pressure. Without the need of adding a suitable solvent for treatment, the total flavonoids of the active part of the broad-leaved grass can be obtained, which saves the production monthly energy. From the perspective of large-scale production, the new extraction and purification process reduces the production cost, shortens the production cycle, and the process is simple and feasible, and meets the requirements of the modernization industry of traditional Chinese medicine.
- the invention adopts AB-8 macroporous adsorption resin technology to extract and purify the effective part, has the advantages of simple process, low cost, reusable resin, and is suitable for industrial production. Moreover, the present invention makes a detailed and in-depth examination of the corresponding technical parameters, optimizes the optimal conditions, and carries out the test of the intermediate test, which can be transferred to industrialization and improve the content of the effective part.
- the total flavonoid extracts of Lysimachia chinensis the total flavonoid content of Radix Paeoniae Alba can reach 50%-80%, and the content of Schiffin can reach 3.0%-12.0%.
- the original ordinary wet granulation process is changed to the fluidized bed granulation process, and it is found that the granulation effect is obviously improved, and the new process is remarkable compared with the original process.
- the dissolution rate of total flavonoids of Herba Lysimachia chinensis L. is improved, the dissolution rate can be stabilized between 88-92%, and the difference in dissolution between batches is small. This method effectively ensures the quality of the product and improves the active ingredients.
- the formulation has stable stability, simple process and strong operability, and is completely suitable for industrial large-scale production.
- the total flavonoid capsules obtained by the invention have the advantages of advanced production technology, clear basis of effective drug substances, controllable quality standards, relatively accurate clinical indications, and remarkable pharmacological effects. With the characteristics of low dosage, safe and convenient administration, and small adverse reactions, it has the advantages of adapting to the modern manufacturing technology and quality standards. Indications: To remove damp heat, diuretic stone, for leaching and sputum caused by damp heat accumulation, urinary calculi and the above syndrome.
- Figure 1 shows the in vitro dissolution profile of the prepared total flavonoids of Herba fuliginea (Example 7) according to one embodiment of the present invention
- Fig. 2 is a graph showing the in vitro dissolution comparison of the total flavonoids of Herba fuliginea prepared by the fluidized bed granulation method and the conventional wet granulation process according to an embodiment of the present invention. detailed description
- the above filtrate (loading solution) is passed through the AB-8 macroporous adsorption resin column at a flow rate of 3 times the bed volume per hour. After the adsorption is completed, the impurity is eluted with 12 times of the amount of the resin, and then 10 times of the column is used.
- the bed volume of 95% ethanol was eluted at a flow rate of 3 times the bed volume per hour to obtain an eluate; the eluate was recovered to ethanol, concentrated to a relative density of 1.10, and dried under reduced pressure at 75 ° C. , crushed, and obtained 4.03 g of total flavonoid extract product of Lysimachia chinensis (preserved in a cool place).
- the extract product was measured by ultraviolet-visible spectrophotometry to obtain the content of the substance in the extract, and the total flavonoid content (% by dry product) was 71.65%, and the content of safflower glycoside (% by dry product) was 10.30%. .
- the above filtrate (loading solution) is passed through the AB-8 macroporous adsorption resin column at a flow rate of 1 column bed per hour. After the adsorption is completed, the impurity is eluted with 10 times of resin amount, and then 8 times column is used. Bed volume of 60% ethanol, at 2 per hour The flow rate of the bed volume is eluted to obtain an eluate; the eluate is recovered into ethanol, concentrated to a concentrated liquid having a relative density of 1.22, dried under reduced pressure at 75 ° C, and pulverized to obtain a total flavonoid extract of Herba Lysimachia. The product is 4.68g (storage in a cool place).
- the extract product was measured by ultraviolet-visible spectrophotometry to obtain the content of the substance in the extract, and the total flavonoid content (% by dry product) was 63.31%, and the content of safflower glycoside (% by dry product) was 5.38%. .
- the above filtrate (loading solution) is passed through the AB-8 macroporous adsorption resin column at a flow rate of 2 times the bed volume per hour. After the adsorption is completed, the impurity is eluted with 10 times of resin amount, and then 8 times column is used.
- the bed volume of 60% ethanol was eluted at a flow rate of 2 times the bed volume per hour to obtain an eluate; the eluate was recovered to ethanol, concentrated to a concentrate having a relative density of 1.22, and dried under reduced pressure at 75 ° C. , crushed, obtained 1.12 kg of total flavonoids extract of Herba Lysimachia (stored in a cool place).
- the extract product was measured by ultraviolet-visible spectrophotometry to obtain the content of the substance in the extract, and the total flavonoid content (% by dry product) was 59.49%, and the content of safflower glycoside (% by dry product) was 5.10%. .
- the above filtrate (loading solution) is passed through the AB-8 macroporous adsorption resin column at a flow rate of 2 times the bed volume per hour. After the adsorption is completed, the impurity is eluted with 10 times of resin amount, and then 8 times column is used.
- the bed volume of 60% ethanol was eluted at a flow rate of 2 times the bed volume per hour to obtain an eluate; the eluate was recovered to ethanol, concentrated to a concentrate having a relative density of 1.22, and dried under reduced pressure at 75 ° C. , crushed, and obtained 1.14 kg of total flavonoid extract of Herba Lysimachia (preserved in a cool place).
- the extract product was measured by ultraviolet-visible spectrophotometry to obtain the content of the substance in the extract, and the total flavonoid content (% by dry product) was 59.37%, and the content of safflower glycoside (% by dry product) was 5.01%. .
- the dried granules are cooled and discharged, passed through a 60-mesh sieve, and granulated, and filled with capsules to obtain 1000 tablets of total flavonoids.
- Dissolution method According to the Chinese Pharmacopoeia 2010 edition two appendix XC first method of dissolution measurement method, using 1000ml of water as the dissolution medium, the rotation speed is 100 rpm, according to the law, after 5, 15, 25, 35 At 45 and 60 minutes, take 10ml of the solution, filter it, and accurately measure the filtrate into 1ml and 5ml volumetric flask, dilute to the mark with 0.1M hydrochloric acid, shake well, as the test solution; take Xiafu glycoside control Appropriate amount, accurately weighed, dissolved in an appropriate amount of ethanol, and diluted with 0.1 M hydrochloric acid to prepare a solution containing about 15 ⁇ g of sulphate per 1 ml as a reference solution.
- Dissolution measurement method In the same manner as in Example 5, the dissolution rate was determined to be 89.9%.
- Dissolution measurement method In the same manner as in Example 5, the dissolution rate was determined to be 90.5%.
- Dissolution measurement method In the same manner as in Example 5, the dissolution was measured to be 90.0%.
- Example 12 Preparation of total flavonoid capsules of Herba Lysimachia
- Dissolution measurement method The same as Example 5, the dissolution rate was determined to be 88.9%, and Example 21, Preparation of the total flavonoid capsule of Herba Lysimachia
- the preparation method of the total flavonoids of the comatus of the comparative example was the same as that of the embodiment 4 of the present invention; the prescription of the comparative example was the same as that of the embodiment 6 of the present invention.
- the embodiment of the present invention adopts a fluidized bed granulation process to obtain a total flavonoid capsule of the genus Lysimachia chinensis
- the comparative example adopts a common wet granulation process, and the comparative example is used to prepare a broad money. Grass total flavonoid capsules.
- the preparation method of the comparative example is as follows:
- the dissolution was measured according to the dissolution method of the first method of the Chinese Pharmacopoeia 2010 edition of the second edition of the XC first method described in Example 5.
- the in vitro dissolution curve is plotted with time as the abscissa and cumulative release as the ordinate.
- Experimental group The experiment was divided into 4 groups, namely, the control group (administered 0.5% sodium carboxymethylcellulose), the low-dose group of total flavonoids of Radix Paeoniae Alba (75 mg/kg), and the middle dose of total flavonoids of Radix Paeoniae Alba (150 mg/ Kg), high-dose total flavonoids (300mg/kg) o 10-20 per group.
- the administration route was a one-time gavage, and the administration volume was 0.6 ml/mouse.
- mice in each group were observed 15 minutes after gavage. The observation included mental, gait, eyes, tail, fur and feces, and observed continuously for 60 minutes. Observe 1 more hour.
- mice After observing the general state and behavior of mice, the mice were given small, medium and large doses of total flavonoids (75mg/kg, 150mg/kg, 300mg/kg) on animal behavior, response, activity, mood, There was no significant change in gait, and there was no significant difference compared with the control group.
- the specific data are shown in Table 2.
- mice were given the total flavonoids of the herb, the appropriate amount of normal saline was applied to the ears of the animals, and the double tip was energized with the fish mouth clamp.
- the voltage was 110 volts, and the stimulating time was 0.3 seconds. time.
- mice in each group were tested. The mice were fasted for 12 hours before the experiment. After 1 hour of total flavonoids of Herba Lysimachia, a suspension made of 5% carbon powder and 10% gum arabic was administered, 0.2 ml. /only. The animals were sacrificed 20 minutes after the gavage, and the entire gastrointestinal tract was taken out and placed on a glass plate. The distance between the pylorus and the leading edge of the carbon was measured with a ruler, and the percentage of the gastrointestinal tract was calculated. The results showed that total flavonoids from Herba Lysimachia had no significant effect on gastrointestinal motility in mice. The specific data is shown in Table 4.
- control group rats were given 0.5% sodium carboxymethylcellulose
- four doses of total flavonoids 50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day, 400 mg
- /kg/day can significantly inhibit calcium oxalate in the kidney
- control group rats were given 0.5% sodium carboxymethylcellulose
- three doses of total flavonoids 50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day
- Both can reduce renal pelvis expansion, reduce stone formation rate, reduce renal calcium oxalate knot polymer (P ⁇ 0.01-0.001), and reduce serum creatinine and uric acid content (P ⁇ 0.05-0.01).
- the three doses of total flavonoids (100 mg/kg/day, 200 mg/kg/day, 400 mg/kg/day) It has the function of dissolving stone and reducing the formation of new stones.
- the weight of stones in the 100 mg/kg group was reduced (P ⁇ 0.05)
- the weight of stones in the 200 mg/kg group was reduced (P ⁇ 0.05)
- 20% of the stones were dissolved
- the weight of stones in the 400 mg/kg group was reduced (P ⁇ 0.01), and 30% of the stones were dissolved.
- the total dose of urinary flavonoids in three doses was 6h after one administration, and the total output of normal control was 48.1ml.
- the drug group 76.4-89.5ml was 29-36 ml higher than the normal control group.
- the urine excreted significantly increased the force within 12 hours, which was 12-36% higher than that of the model group.
- the control group was given 0.5% sodium carboxymethylcellulose
- the three doses of total flavonoids 100 mg/kg/day, 200 mg/kg/day, 400 mg/kg/day
- the total flavonoid capsule of Desmodium styracifolium has certain anti-inflammatory effect and has obvious inhibitory effect on granulation tissue proliferation.
- Example 26 Animal acute toxicity test of total flavonoid capsules of Herba Lysimachia
- the test was divided into 6 groups, 20 animals in each group, half male and half female, with a distance between the groups of 0.85. After the drug, the animals showed less activity, unstable gait, and weak breathing. Most of the dead animals were distributed within 1 hour after the drug, and individual dead animals were distributed 1-6 hours after the drug.
- the LD50 of female animals is 18.162g/kg, 95% confidence limit
- the upper limit is 20.199g/kg
- the lower limit is 16.326g/kg
- the male animal LD50 is 17.084g/kg
- 95% confidence limit The upper limit is 18.975g/kg and the lower limit is 15.301g/kg. There was no significant difference in LD50 between females and males. Based on the above results, it can be considered that the total flavonol is a substantially non-toxic test drug.
- the test was carried out according to the Single Oral Fixed Dose Method.
- the rats were administered at 2000 mg/kg.
- the animals had no obvious acute toxicity, so a formal test was performed at a fixed dose of 2000 mg/kg.
- the test was divided into the control group and the total flavonoids group of D. chinensis, with 10 animals in each group, half male and half female.
- the animals in the drug-administered group were intragastrically administered with total flavonoids of 2000 mg/kg, and the volume was 2.0 ml/100 g body weight.
- the control animals were intragastrically administered with 0.5% sodium carboxymethylcellulose 2.0 ml/100 g body weight.
- the lazy movement occurred within 3 hours after the drug was administered.
- the stool was grayish black one day after the drug, the food intake decreased slightly, the weight gain was slightly inhibited, and the drug returned to the control level 7 days after the drug. Based on the above results, it can be considered that the total flavonoids of T. chinensis is a test drug without the risk of serious acute poisoning.
- Example 27 Animal long-term toxicity test of total flavonoid capsules of Herba Lysimachia
- test design was low, medium and high 200mg/kg/day, 600mg/kg/day, 1800mg/kg/day three dose groups and the control group (control group rats were administered 0.5% sodium carboxymethylcellulose), which was about equivalent It is 11.7 times, 35.1 times, and 105.3 times the dosage of human.
- the route of administration was gavage, 6 times a week for 26 weeks.
- the test animals were observed for general drug response, urine biochemistry, peripheral blood formation, clotting time, serum biochemistry, organ weight, and histopathology.
- the aspartate aminotransferase of the high-dose group was significantly higher than that of the control group (P ⁇ 0.05); serum bilirubin total
- the content of males and females in the middle dose group was significantly higher than that in the control group (P ⁇ 0.05).
- the serum total cholesterol level of the high dose group was significantly lower than that of the control group (P ⁇ 0.01).
- the serum total cholesterol level in the middle dose group was still significantly lower than that in the control group.
- test animals survived to a predetermined treatment time.
- each group of animals had a bright coat, good appetite and normal body temperature.
- 4.5-6.0 months after the drug some animals in the high-dose group had slightly worse appetite.
- the above-mentioned observed indicators were restored to the level of the control group.
- the weight gain of the high-dose group was significantly inhibited during the administration period, and administered for 6.0 months, compared with the normal control group. The difference is obvious.
- the above observed indicators returned to the level of the control group; after administration for 6.0 months, the levels of aspartate aminotransferase activity and urea nitrogen in the high dose group were significantly higher than those in the control group; During the period, the total bilirubin and total cholesterol levels in each group increased; one month after stopping the drug, the above indicators returned to normal levels.
- Example 28 The treatment of urinary calculi (damp heat accumulation) with medicinal flavonoids in the treatment of urinary tract stones (wet heat accumulation) Double-blind, multi-dose, parallel-controlled, multicenter, phase II clinical trial
- Inclusion criteria for clinical trials (1) renal calculi and ureteral stones; (2) age between 18 and 65 years; (3) stone diameter 0.4 ( ⁇ 1 ⁇ stone diameter 1.0 cm; (4) good renal function, especially The side kidney function is good. If the patient has hydronephrosis, the degree of hydronephrosis is below moderate; (5) The general condition is good, and the life can be self-care; (6) Informed consent to the study, and signed informed consent.
- Clinical trial exclusion criteria (1) Renal, ureteral junction, or ureter distal to the ureter with malformations, stenosis, obstruction, and surgical scar adhesion; (2) severe (type III) hydronephrosis; (3) persistent severe hematuria, Even shock; (4) acute obstructive oliguria, no urine; (5) pregnant, lactating women; (6) combined with cardiovascular disease, liver, kidney, hematopoietic system and other serious primary diseases, or affect their survival Serious illness (such as cancer or AIDS), or mentally or legally disabled patients; (7) liver function ALT and / or AST values outside the normal value; (8) used surgical intervention for urolithiasis in the past month (9) According to the judgment of the researcher, other lesions that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in the working environment, may cause loss of follow-up; (10) participated in the past three months. Drug clinical trial; (11) known to be allergic to the drug or its components.
- Group A - - High dose group Total flavonoid capsule of Rhododendron chinense X 5;
- Group B Medium dose group: Total flavonoid capsule of Rhododendron chinense X 3 capsules 10 simulant X 2;
- Group C - very low dose group total flavonoid capsule mimetic agent X 5 .
- Subjects Patients who met the diagnosis of renal calculus and ureteral calculi, and the syndrome differentiation of traditional Chinese medicine in accordance with the damp heat accumulation syndrome, aged 18 to 65 years, voluntarily signed informed consent.
- Dosing regimen Total flavonoids of Herba Lysimachia, oral, 5 capsules per dose / 3 capsules + 2 tablets of amyloid / 5 capsules, 3 times a day; (Note: Total flavonoids and medicinal herbs
- the total flavonoid capsule simulant specifications are: 0.20 g / granule; chlorophyll total flavonoid capsules contain 133 mg of total flavonoids per capsule; total flavonoid capsule mimetic capsule contains 1.33 mg of total flavonoids per capsule).
- Dosing cycle 4 weeks.
- the effectiveness evaluation indicators include: (1) X-ray examination (KUB, IVP, Ctu/Mru/CT); (2) Single examination: symptoms, signs; (3) TCM syndrome points.
- Safety evaluation indicators include: (1) physical examination, including body temperature, respiration, heart rate, resting blood pressure, etc.; (2) blood routine, urine routine, liver function (ALT, AST, Tbil, ALP, Y-GT), kidney Function (Cr, Bun), coagulation test, total cholesterol; (3) electrocardiogram; (4) adverse events.
- Full Analysis Set An ideal set of subjects (including all randomized enrollments and at least one treatment), as close as possible to the principle of intentional analysis.
- PPS Per Protocol Set
- Safety Analysis Set All subjects who received at least one treatment after randomization.
- the main variables and comprehensive efficacy analysis were selected from the full analysis set and the compliance set; the demographic and other baseline characteristics were selected from the full analysis set, and other efficacy indicators were selected to meet the set of programs; the safety index analysis used the safety set.
- 22 patients in the high-dose group, 23 in the middle-dose group, and 22 in the very low-dose group entered the FAS episode.
- 20 patients in the high-dose group, 22 in the middle-dose group, and 22 in the very low-dose group entered the PPS episode, and 22 patients in the high-dose group.
- Twenty-three patients in the middle dose group and 22 patients in the very low dose group entered the SS set.
- 2 patients in the middle-dose group and 2 patients in the middle-dose group were absent, and 1 in the middle-dose group was excluded.
- a structure, material or feature is included in at least one embodiment or example of the invention.
- the schematic representation of the above terms does not necessarily mean the same embodiment or example.
- the particular features, structures, materials, or characteristics described may be combined in a suitable manner in any one or more embodiments or examples.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/101,924 US9724374B2 (en) | 2013-12-05 | 2014-07-15 | Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use |
KR1020167017638A KR20160117426A (ko) | 2013-12-05 | 2014-07-15 | 광동금전초 총플라보노이드 캡슐 및 그의 제조 방법과 용도 |
BR112016012489A BR112016012489A2 (pt) | 2013-12-05 | 2014-07-15 | cápsula, método de preparação de uma cápsula contendo flavonoides totais de desmodium styracifolium, e uso da cápsula |
AU2014360040A AU2014360040B2 (en) | 2013-12-05 | 2014-07-15 | Desmodium styracifolium (Osb.) Merr. flavonoids capsule, method of preparing same, and application thereof |
EP14868261.0A EP3078380A4 (en) | 2013-12-05 | 2014-07-15 | Desmodium styracifolium (osb.) merr. flavonoids capsule, method of preparing same, and application thereof |
CA2931528A CA2931528A1 (en) | 2013-12-05 | 2014-07-15 | Desmodium styracifolium (osb.) merr. flavonoids capsule, method of preparing same, and application thereof |
SG11201604222YA SG11201604222YA (en) | 2013-12-05 | 2014-07-15 | Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use |
JP2016557172A JP2016540833A (ja) | 2013-12-05 | 2014-07-15 | 広金銭草総フラボノイドカプセル剤およびその製造方法、並びにその応用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310643107.3 | 2013-12-05 | ||
CN201310643107.3A CN103893246A (zh) | 2013-12-05 | 2013-12-05 | 广金钱草总黄酮胶囊及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015081701A1 true WO2015081701A1 (zh) | 2015-06-11 |
Family
ID=50985033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/082224 WO2015081701A1 (zh) | 2013-12-05 | 2014-07-15 | 广金钱草总黄酮胶囊及其制备方法和应用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9724374B2 (zh) |
EP (1) | EP3078380A4 (zh) |
JP (1) | JP2016540833A (zh) |
KR (1) | KR20160117426A (zh) |
CN (1) | CN103893246A (zh) |
AU (1) | AU2014360040B2 (zh) |
BR (1) | BR112016012489A2 (zh) |
CA (1) | CA2931528A1 (zh) |
SG (1) | SG11201604222YA (zh) |
WO (1) | WO2015081701A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893258B (zh) * | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
CN103893247A (zh) * | 2013-12-05 | 2014-07-02 | 人福医药集团股份公司 | 药物组合物及其制备方法和用途 |
CN104974176B (zh) * | 2015-06-19 | 2018-08-14 | 武汉光谷人福生物医药有限公司 | 从广金钱草中提取分离广金钱草碱的方法和系统 |
CN105085498B (zh) * | 2015-06-19 | 2018-11-02 | 武汉光谷人福生物医药有限公司 | 从广金钱草中提取分离异牡荆素的方法和系统 |
CN105092744B (zh) * | 2015-08-31 | 2017-07-28 | 武汉光谷人福生物医药有限公司 | 广金钱草总黄酮提取物的特征图谱及其建立方法和应用 |
CN105079084B (zh) * | 2015-08-31 | 2019-11-01 | 武汉光谷人福生物医药有限公司 | 从广金钱草中提取总黄酮提取物的方法和测定广金钱草中有效成分含量的方法 |
KR101870818B1 (ko) * | 2017-07-28 | 2018-07-20 | 배진식 | 한방용 환 및 그의 제조방법 |
CN110376142B (zh) * | 2019-08-20 | 2022-07-01 | 陕西中医药大学 | 中药红花质量等级的检测方法 |
CN114424823B (zh) * | 2022-01-20 | 2023-07-04 | 江苏海王健康生物科技有限公司 | 一种含天然提取物的降血脂软胶囊及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102232993A (zh) * | 2011-05-06 | 2011-11-09 | 南京泽朗医药科技有限公司 | 一种从广金钱草中提取总黄酮的方法 |
CN103893258A (zh) * | 2013-12-05 | 2014-07-02 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
CN103893247A (zh) * | 2013-12-05 | 2014-07-02 | 人福医药集团股份公司 | 药物组合物及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61200921A (ja) * | 1985-03-04 | 1986-09-05 | Kao Corp | 皮脂腺機能抑制剤 |
JPH01301688A (ja) * | 1988-05-31 | 1989-12-05 | Nippon Mektron Ltd | トリテルペノイダルサポニン、その製造法ならびにそれを有効成分とする腎臓結石予防剤 |
JPH01305080A (ja) * | 1988-06-01 | 1989-12-08 | Nippon Mektron Ltd | フラボノイドを有効成分とする腎臓結石予防剤ならびにその製造法 |
CN1042544A (zh) * | 1988-11-08 | 1990-05-30 | 王杆柔 | 金钱草的主成分(三萜皂角醇和黄酮甙)的提取法 |
CN1453274A (zh) * | 2002-04-26 | 2003-11-05 | 中国人民解放军军事医学科学院放射医学研究所 | 一种黄酮类化合物治疗尿石症、胆石症的用途及其制备工艺 |
CN100417408C (zh) * | 2007-06-29 | 2008-09-10 | 广西万通制药有限公司 | 一种清热祛湿、利水通淋、消炎止痛、排石的中药制剂、制备方法及应用 |
CN101249135A (zh) * | 2008-03-28 | 2008-08-27 | 湖南长沙宝鉴生物工程有限公司 | 复方石淋通胶囊及其制备工艺 |
CN102451218A (zh) * | 2010-10-19 | 2012-05-16 | 天津丹溪国药研究所 | 一种中药成方石淋通口服液的制备方法 |
CN102772441A (zh) * | 2012-07-06 | 2012-11-14 | 周明千 | 中药超微破壁胶囊剂饮片的加工方法 |
-
2013
- 2013-12-05 CN CN201310643107.3A patent/CN103893246A/zh active Pending
-
2014
- 2014-07-15 US US15/101,924 patent/US9724374B2/en active Active
- 2014-07-15 WO PCT/CN2014/082224 patent/WO2015081701A1/zh active Application Filing
- 2014-07-15 BR BR112016012489A patent/BR112016012489A2/pt not_active IP Right Cessation
- 2014-07-15 EP EP14868261.0A patent/EP3078380A4/en not_active Withdrawn
- 2014-07-15 SG SG11201604222YA patent/SG11201604222YA/en unknown
- 2014-07-15 CA CA2931528A patent/CA2931528A1/en not_active Abandoned
- 2014-07-15 AU AU2014360040A patent/AU2014360040B2/en not_active Ceased
- 2014-07-15 KR KR1020167017638A patent/KR20160117426A/ko not_active Application Discontinuation
- 2014-07-15 JP JP2016557172A patent/JP2016540833A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102232993A (zh) * | 2011-05-06 | 2011-11-09 | 南京泽朗医药科技有限公司 | 一种从广金钱草中提取总黄酮的方法 |
CN103893258A (zh) * | 2013-12-05 | 2014-07-02 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
CN103893247A (zh) * | 2013-12-05 | 2014-07-02 | 人福医药集团股份公司 | 药物组合物及其制备方法和用途 |
Non-Patent Citations (3)
Title |
---|
"Chinese Pharmacopoeia", 2010 |
See also references of EP3078380A4 |
WEIN, JIN ET AL.: "Comparative Study on Two Pelleting Process of Shenbai Granula", CHINESE TRADITIONAL PATENT MEDICINE, vol. 33, no. 09, 30 September 2011 (2011-09-30), pages 1615 - 1617, XP008183579 * |
Also Published As
Publication number | Publication date |
---|---|
AU2014360040B2 (en) | 2017-02-02 |
US9724374B2 (en) | 2017-08-08 |
US20160296579A1 (en) | 2016-10-13 |
BR112016012489A2 (pt) | 2017-09-26 |
EP3078380A4 (en) | 2017-05-24 |
EP3078380A1 (en) | 2016-10-12 |
KR20160117426A (ko) | 2016-10-10 |
CN103893246A (zh) | 2014-07-02 |
AU2014360040A1 (en) | 2016-06-16 |
JP2016540833A (ja) | 2016-12-28 |
SG11201604222YA (en) | 2016-07-28 |
CA2931528A1 (en) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015081701A1 (zh) | 广金钱草总黄酮胶囊及其制备方法和应用 | |
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN101366721B (zh) | 一种治疗骨科疾病的原料药及其制备方法 | |
WO2015081702A1 (zh) | 药物组合物及其制备方法和用途 | |
WO2015081703A1 (zh) | 一种含有广金钱草总黄酮的固体分散体及其制备方法和用途 | |
EP2172206A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
CN109718273B (zh) | 紫苏叶提取物在预防或治疗骨性关节炎中的应用 | |
CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
CN103356630B (zh) | 含有己酮可可碱和普卡必利的药物组合物及其医药用途 | |
CN100563647C (zh) | 灯盏花和丹参酮ⅱa磺酸钠的药用组合物 | |
CN103784683B (zh) | 一种治疗肥胖症的中药组合物及其制备方法和应用 | |
CN101244068B (zh) | 雪胆素缓释制剂 | |
CN1969937B (zh) | 一种治疗肝炎的药物组合物 | |
CN107669738B (zh) | 一种活血化瘀、益气强心的中药制剂及其制备方法 | |
CN103816466A (zh) | 一种治疗胸痹心痛的中药组合物及其制剂和制备方法 | |
CN101773546A (zh) | 丹参有效成分同步定位释药微丸及其制备方法 | |
CN111068024A (zh) | 一种中药复方制剂及其制备方法 | |
CN115252710B (zh) | 一种用于治疗便秘的药物的制备方法、所制药物及其应用 | |
CN116077602B (zh) | 一种傣药组合物、药物制剂及其制备方法和用途 | |
CN112386671B (zh) | 一种治疗间质性肺疾病的中药组合物及其应用 | |
CN102058869B (zh) | 一种木香顺气胃漂浮制剂及其制备方法 | |
US20110071225A1 (en) | Method for obtaining a sequoyitol-containing extract from genus nephrolepis and uses thereof | |
CN117919331A (zh) | 中药组合物在制备治疗慢性充血性心力衰竭保健食品或药品中的应用 | |
CN1155389C (zh) | 用胡椒碱增加芍药甙生物利用度的复方中药及制备方法 | |
CN117919346A (zh) | 治疗高尿酸血症和痛风性关节炎的药食同源中药复方及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14868261 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2931528 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016557172 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15101924 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016012489 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2014868261 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014868261 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014360040 Country of ref document: AU Date of ref document: 20140715 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167017638 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016126588 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016/0597.1 Country of ref document: KZ |
|
ENP | Entry into the national phase |
Ref document number: 112016012489 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160601 |